Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study

References

• Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi: 10.1038/s41582-019-0210-4.
   PubMed Web of Science ®Google Scholar
• Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8(2):117–127. doi: 10.1007/s12265-015-9613-9.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–638. doi: 10.3109/07853890.2015.1068949.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520–528. doi: 10.1093/eurheartj/ehs123.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maurer MS, Suhr OB. THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63–76. doi: 10.1185/03007995.2012.754348.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi: 10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. doi: 10.1056/NEJMoa1716793.
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Supplement 1):S14–S26. doi: 10.1097/WCO.0000000000000289.
   PubMedGoogle Scholar
• Obici L, Kuks JB, Buades J, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29(Supplement 1):S27–S35. doi: 10.1097/WCO.0000000000000290.
   PubMedGoogle Scholar
• Adams D, Polydefkis M, González-Duarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021;20(1):49–59. doi: 10.1016/S1474-4422(20)30368-9.
   PubMed Web of Science ®Google Scholar
• Gundapaneni BK, Sultan MB, Keohane DJ, et al. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464–468. doi: 10.1111/ene.13510.
   PubMed Web of Science ®Google Scholar
• Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. Curr Opin Neurol. 2012;25(5):564–572. doi: 10.1097/WCO.0b013e328357bdf6.
   PubMed Web of Science ®Google Scholar
• Adams D, Lozeron P, Theaudin M, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid. 2012;19(Supplement 1):61–64. doi: 10.3109/13506129.2012.685665.
   PubMedGoogle Scholar
• Mazzeo A, Russo M, Di Bella G, et al. Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area. J Neuromuscul Dis. 2015;2(s2):S39–S48. doi: 10.3233/JND-150091.
   PubMedGoogle Scholar
• Alves-Ferreira M, Coelho T, Santos D, et al. A trans-acting factor may modify age at onset in familial amyloid polyneuropathy ATTRV30M in Portugal. Mol Neurobiol. 2018;55:3676–3683. doi: 10.1007/s12035-017-0593-4.
   PubMed Web of Science ®Google Scholar
• Plante-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet. 2003;40:e120. doi: 10.1136/jmg.40.11.e120.
   PubMed Web of Science ®Google Scholar
• Gunnarsson M, Malmeström C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69(1):83–89. doi: 10.1002/ana.22247.
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther. 2018;10:71. doi: 10.1186/s13195-018-0404-9.
   PubMed Web of Science ®Google Scholar
• Lin YS, Lee WJ, Wang SJ, et al. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep. 2018;8(1):17368. doi: 10.1038/s41598-018-35766-w.
   PubMedGoogle Scholar
• Byrne LM, Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017;16(8):601–609. doi: 10.1016/S1474-4422(17)30124-2.
   PubMed Web of Science ®Google Scholar
• Bischof A, Manigold T, Barro C, et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis. 2018;77(7):1093–1094. doi: 10.1136/annrheumdis-2017-212045.
   PubMed Web of Science ®Google Scholar
• van Lieverloo GGA, Wieske L, Verhamme C, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2019;24(2):187–194. doi: 10.1111/jns.12319.
   PubMed Web of Science ®Google Scholar
• Mariotto S, Farinazzo A, Magliozzi R, et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 2018;23(3):174–177. doi: 10.1111/jns.12279.
   PubMed Web of Science ®Google Scholar
• Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518–e524. doi: 10.1212/WNL.0000000000004932.
   PubMed Web of Science ®Google Scholar
• Lycke JN, Karlsson JE, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(3):402–404. doi: 10.1136/jnnp.64.3.402.
   PubMed Web of Science ®Google Scholar
• Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019;25(2):277–283. doi: 10.1038/s41591-018-0304-3.
   PubMed Web of Science ®Google Scholar
• Louwsma J, Brunger AF, Bijzet J, et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid. 2021;28(1):50–55. doi: 10.1080/13506129.2020.1815696.
   PubMed Web of Science ®Google Scholar
• Ticau S, Sridharan GV, Tsour S, et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology. 2021;96(3):e412–e422. doi: 10.1212/WNL.0000000000011090.
   PubMed Web of Science ®Google Scholar
• Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733–748. doi: 10.1002/msj.21352.
   PubMedGoogle Scholar
• Suanprasert N, Berk JL, Benson MD, et al. Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials. J Neurol Sci. 2014;344(1–2):121–128. doi: 10.1016/j.jns.2014.06.041.
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Conceição I, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2020;15(1):179. doi: 10.1186/s13023-020-01399-4.
   PubMed Web of Science ®Google Scholar
• Dyck PJB, González-Duarte A, Obici L, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS+7. J Neurol Sci. 2019;405:116424. doi: 10.1016/j.jns.2019.116424.
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19(2):104–114. doi: 10.1111/jns5.12059.
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals Inc. Patisiran global open-label long-term extension study protocol; 2021 [cited 2023 Mar 27]. Available from: https://www.alnylam.com/OLE-Study-Protocol-Amendment.pdf.
   Google Scholar
• Adams D, Coelho T, Conceição I, et al. Phase 2 open-label extension (OLE) study of patisiran, an investigational RNAi therapeutic for the treatment of polyneuropathy due to hereditary ATTR (hATTR) amyloidosis: final 24-month data. Neurology. 2017;88(16 Supplement):S24.004.
   Google Scholar
• Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120–1127. doi: 10.1093/eurheartj/ehr383.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi: 10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS). Am Heart J. 2012;164(2):222–228 e1. doi: 10.1016/j.ahj.2012.04.015.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667. doi: 10.1001/jama.2013.283815.
   PubMed Web of Science ®Google Scholar
• Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, et al. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid. 2013;20(4):263–268. doi: 10.3109/13506129.2013.845745.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Foiani M, Heslegrave A, et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst. 2019;24(4):314–319. doi: 10.1111/jns.12350.
   PubMedGoogle Scholar
• Maia LF, Maceski A, Conceição I, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 2020;27(2):97–102. doi: 10.1080/13506129.2019.1708716.
   PubMed Web of Science ®Google Scholar
• Luigetti M, Di Paolantonio A, Guglielmino V, et al. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience. Neurol Sci. 2022;43(4):2845–2848. doi: 10.1007/s10072-021-05850-7.
   PubMed Web of Science ®Google Scholar
• Thebault S, Booth RA, Freedman MS. Blood neurofilament light chain: the neurologist’s troponin? Biomedicines. 2020;8(11):523. doi: 10.3390/biomedicines8110523.
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein? Brain. 2018;141(8):2235–2237. doi: 10.1093/brain/awy200.
   PubMedGoogle Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–829. doi: 10.1056/NEJMoa1208760.
   PubMed Web of Science ®Google Scholar
• Mariani LL, Lozeron P, Theaudin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol. 2015;78(6):901–916. doi: 10.1002/ana.24519.
   PubMed Web of Science ®Google Scholar
• Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854. doi: 10.1097/TP.0000000000000574.
   PubMed Web of Science ®Google Scholar